Organ transplants are one of the greatest advances in modern day medicine. Organ transplantation is a medical procedure in which an organ is removed from one body and transferred to another body to replace the missing or damaged organ. One of the most important aspect of the organ transplantation is the consent of the patient or the family of the patient. Organ harvesting without proper consent is illegal and a massive crime. Organ transplantation is mostly carried out with the brain dead patient who’s other organs are healthy and can be used to save another person’s life. The process of organ transplantation needs to be done right after the death of the patient or within a couple of hours. Kidneys are the most widely transplanted organ which is followed by liver. Unfortunately, the need for organ donors is much higher than the number of people who donate organs. According to the National Kidney Foundation, more than 3,000 new patients are added to the kidney waiting list each month worldwide. According to United Network for Organ Sharing, 21 people die everyday in the United States waiting for an organ, and more than 120,000 men, women and children await lifesaving organ transplants.
One company dedicated to improving the lives of organ transplant patients through noninvasive diagnostics is CareDx, Inc. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx strives to stay at the forefront of organ transplant surveillance solutions. Based in Brisbane, Calif., CareDx stock (Nasdaq: CDNA) leads the medical services sector with a major upswing over the past year for investors.
Shares of CDNA are up 402 percent over the last 52 weeks (Nov. 20, 2017 to Nov. 16, 2018). This year alone, the stock is up 308 percent, closing Friday at $29.95 per share, up 0.81 percent for the day. CDNA has a 52-week low of $4.92 and high of $30.15.
The only dividend stock I see in the medical services sector comes from Global Cord Blood Corp. (NYSE: CO).
Global Cord Blood Corp.
Global Cord Blood Corp. is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and no new licenses will be granted before 2020 in addition to the seven licenses authorized as of today. Global Cord Blood Corp. provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services.
Shares of CO are down 40 percent over the last 52 weeks (Nov. 20, 2017 to Nov. 16, 2018). This year alone, the stock is down 34 percent, closing Friday at $6.53 per share, down 2 percent for the day. CO has a 52-week low of $6.01 and high of $12.25. The company issued a $0.08 dividend on July 31, 2018.
Disclaimer: This post is provided for information purposes only and should not be used as the basis for any investment decision. I am neither licensed nor qualified to provide investment advice. Keith Stein has no position in any stocks mentioned in this post. DCNewsroom has no position in any of the stocks mentioned in this post.
I am in favor of immediate donor/organ/transplants. However, I believe there is a big grey area in banking cord blood or any other kind of "banking" for later use. Too many possibilities for misuse or mix-ups.
Post a Comment